Loading stock data…
$802.64-9.66 (-1.19%)
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
argenx SE in the Healthcare sector is trading at $802.64 with a market capitalization of $54.0B. Wall Street consensus targets $1,152.65 (23 analysts), implying a +43.6% move over the next 12 months. The stock is currently 25% below its 52-week high of $1,072.75, remaining 5.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 21 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.51B↑ | $1.30B↑ | $1.29B↑ | $1.13B↑ | $947.96M |
| Gross Profit | $1.37B↑ | $1.18B↑ | $1.14B↑ | $1.02B↑ | $837.21M |
| Operating Income | $494.00M↑ | $394.00M↑ | $359.56M↑ | $349.97M↑ | $203.84M |
| Net Income | $472.00M↑ | $366.00M↓ | $532.95M↑ | $344.26M↑ | $245.36M |
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and imm...